Nathalie Timmerman

Ms. Nathalie Timmerman

MD, PhD candidate

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
NNNick S. Nurmohamed
Nick S. Nurmohamed
JPJoão P. Belo Pereira
João P. Belo Pereira
RHRenate M. Hoogeveen
Renate M. Hoogeveen
JKJeffrey Kroon
Jeffrey Kroon
JKJordan M. Kraaijenhof
Jordan M. Kraaijenhof
ESErik S.G. Stroes
Erik S.G. Stroes
Current risk scores do not accurately identify patients at highest risk of recurrent atherosclerotic cardiovascular disease (ASCVD) in need of more intensive therapeutic interventions. Advances in high-throughput plasma proteomics, analysed with machine learning techniques, may offer new opportunities to further improve risk stratification in these patients. Targeted plasma proteomics was performed in two secondary prevention cohorts: the Second Manifestations of ARTerial disease (SMART) cohort (n = 870) and the Athero-Express cohort (n = 700). The primary outcome was recurrent ASCVD (acute myocardial infarction, ischaemic stroke, and cardiovascular death). Machine learning techniques with extreme gradient boosting were used to construct a protein model in the derivation cohort (SMART), which was validated in the Athero-Express cohort and compared with a clinical risk model. Pathway analysis was performed to identify specific pathways in high and low C-reactive protein (CRP) patient subsets. The protein model outperformed the clinical model in both the derivation cohort [area under the curve (AUC): 0.810 vs. 0.750; P < 0.001] and validation cohort (AUC: 0.801 vs. 0.765; P < 0.001), provided significant net reclassification improvement (0.173 in validation cohort) and was well calibrated. In contrast to a clear interleukin-6 signal in high CRP patients, neutrophil-signalling-related proteins were associated with recurrent ASCVD in low CRP patients. A proteome-based risk model is superior to a clinical risk model in predicting recurrent ASCVD events. Neutrophil-related pathways were found in low CRP patients, implying the presence of a residual inflammatory risk beyond traditional NLRP3 pathways. The observed net reclassification improvement illustrates the potential of proteomics when incorporated in a tailored therapeutic approach in secondary prevention patients. Targeted proteomics in two secondary prevention cohorts outperforms a clinical risk model in terms of discrimination and reclassification. The involvement of neutrophil-related pathways was found in the subset of low C-reactive protein patients. ASCVD, atherosclerotic cardiovascular disease; AUC, area under the curve; NRI, net reclassification improvement; IDI, integrated discrimination index.

1 October 2020 in Atherosclerosis
Verified
Journal Article
Open access
MBMarie de Bakker
Marie de Bakker
NTNathalie Timmerman
Nathalie Timmerman
IKIan D. van Koeverden
Ian D. van Koeverden
DKDominique P.V. de Kleijn
Dominique P.V. de Kleijn
GBGert J. de Borst
Gert J. de Borst
HRHester M. Den Ruijter
Hester M. Den Ruijter
The sex- and age-related differences in the composition of iliofemoral atherosclerotic plaques are largely unknown. Therefore, the aim of the current study is to gain insight into plaque composition across strata of age and sex in a large cohort of vascular surgery patients. Peripheral atherosclerotic plaques of patients who underwent iliofemoral endarterectomy (n = 790) were harvested between 2002 and 2014. The plaques were semi-quantitatively analyzed for the presence of lipid cores, calcifications, plaque hemorrhages (PH), collagen, macrophage and smooth muscle cell (SMC) content, and quantitatively for microvessel density. Patients were stratified by age tertiles and sex. Ageing was independently associated with rupture-prone iliofemoral plaque characteristics, such as higher prevalence of plaque calcifications (OR 1.52 (95%CI:1.03-2.24) p = 0.035) and PH (OR 1.46 (95%CI:1.01-2.09) p = 0.042), and lower prevalence of collagen (OR 0.52 (95%CI:0.31-0.86) p = 0.012) and SMCs (OR 0.59 (95%CI:0.39-0.90) p = 0.015). Sex-stratified data showed that men had a higher prevalence of lipid cores (OR 1.62 (95%CI:1.06-2.45) p = 0.025) and PH (OR 1.62 (95%CI:1.16-2.54) p = 0.004) compared to women. These sex-differences attenuated with increasing age, with women showing an age-related increase in calcifications (p = 0.002), PH (p = 0.015) and decrease in macrophages (p = 0.005). In contrast, men only showed a decrease in collagen (p = 0.043). Atherosclerotic iliofemoral plaques derived from men display more rupture-prone characteristics compared to women. Yet, this difference is attenuated with an increase in age, with older women having more rupture-prone characteristics compared to younger women.

1 November 2019 in Atherosclerosis
Verified
Journal Article
Closed access
LFLeonie M.M. Fassaert
Leonie M.M. Fassaert
NTNathalie Timmerman
Nathalie Timmerman
IKIan D. van Koeverden
Ian D. van Koeverden
GPGerard Pasterkamp
Gerard Pasterkamp
DKDominique P.V. de Kleijn
Dominique P.V. de Kleijn
Gert Jan de BorstGert Jan de Borst
Gert Jan de Borst

20 September 2020 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NTNathalie Timmerman
Nathalie Timmerman
GGGeorge Galyfos
George Galyfos
FSFragiska Sigala
Fragiska Sigala
KTKalliopi Thanopoulou
Kalliopi Thanopoulou
GBGert J. de Borst
Gert J. de Borst
ACall partners of the TAXINOMISIS Consortium
all partners of the TAXINOMISIS Consortium
Introduction: Asymptomatic carotid artery stenosis (ACAS) may cause future stroke and therefore patients with ACAS require best medical treatment. Patients at high risk for stroke may opt for additional revascularization (either surgery or stenting) but the future stroke risk should outweigh the risk for peri/post‐operative stroke/death. Current risk stratification for patients with ACAS is largely based on outdated randomized‐controlled trials that lack the integration of improved medical therapies and risk factor control. Furthermore, recent circulating and imaging biomarkers for stroke have never been included in a risk stratification model. The TAXINOMISIS Project aims to develop a new risk stratification model for cerebrovascular complications in patients with ACAS and this will be tested through a prospective observational multicentre clinical trial performed in six major European vascular surgery centres.Methods and analysis: The risk stratification model will compromise clinical, circulating, plaque and imaging biomarkers. The prospective multicentre observational study will include 300 patients with 50%‐99% ACAS. The primary endpoint is the three‐year incidence of cerebrovascular complications. Biomarkers will be retrieved from plasma samples, brain MRI, carotid MRA and duplex ultrasound. The TAXINOMISIS Project will serve as a platform for the development of new computer tools that assess plaque progression based on radiology images and a lab‐on‐chip with genetic variants that could predict medication response in individual patients.Conclusion: Results from the TAXINOMISIS study could potentially improve future risk stratification in patients with ACAS to assist personalized evidence‐based treatment decision‐making.

Verified
Journal Article
Open access
PDF file
MDMirthe Dekker
Mirthe Dekker
FWFarahnaz Waissi
Farahnaz Waissi
NTNathalie Timmerman
Nathalie Timmerman
MSMax Silvis
Max Silvis
LTLeo Timmers
Leo Timmers
DKDominique De Kleijn
Dominique De Kleijn
Coronary artery disease (CAD), comprising both acute coronary syndromes (ACS) and chronic coronary syndromes (CCS), remains one of the most important killers throughout the entire world. ACS is often quickly diagnosed by either deviation on an electrocardiogram or elevated levels of troponin, but CCS appears to be more complicated. The most used noninvasive strategies to diagnose CCS are coronary computed tomography and perfusion imaging. Although both show reasonable accuracy (80–90%), these modalities are becoming more and more subject of debate due to costs, radiation and increasing inappropriate use in low-risk patients. A reliable, blood-based biomarker is not available for CCS but would be of great clinical importance. Extracellular vesicles (EVs) are lipid-bilayer membrane vesicles containing bioactive contents e.g., proteins, lipids and nucleic acids. EVs are often referred to as the “liquid biopsy” since their contents reflect changes in the condition of the cell they originate from. Although EVs are studied extensively for their role as biomarkers in the cardiovascular field during the last decade, they are still not incorporated into clinical practice in this field. This review provides an overview on EV biomarkers in CCS and discusses the clinical and technological aspects important for successful clinical application of EVs.

2 November 2022 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
MVMaarten C. Verwer
Maarten C. Verwer
JMJoost M. Mekke
Joost M. Mekke
NTNathalie Timmerman
Nathalie Timmerman
QPQiu Y. Van Der Pol
Qiu Y. Van Der Pol
CFClaire Frissen
Claire Frissen
DKDominique De Kleijn
Dominique De Kleijn
Plasma extracellular vesicles (EV) are an emerging source of biomarkers for diagnosis and prognosis of cardiovascular disease (CVD). Risk stratification for common adverse events such as major adverse limb events (MALE) and major adverse cardiovascular events (MACE) by an EV blood sample could improve healthcare management by individualising drug therapy or improving informed decision making regarding revascularisations in patients with peripheral artery disease (PAD). As such, this study investigated the associations between plasma EV proteins and prospectively registered MALE and MACE in consecutive patients undergoing femoral endarterectomy. Using the Athero-Express biobank study, four EV proteins (Cystatin C, CD14, Serpin C1, and Serpin G1) were measured in the high density lipoprotein subfraction isolated from plasma of 317 PAD patients undergoing arterial revascularisation. Multivariable Cox proportional hazard regression was used to investigate the association between plasma EV protein levels and MACE and MALE in the three year post-operative period. Most patients were treated for claudication (Fontaine II, 52.8%), although rest pain (Fontaine III, 30.1%) and ischaemic wounds (Fontaine IV, 17.1%) were common in this cohort. Within three years 51 patients died, amongst whom 25 deaths were due to CVD, 39 patients experienced a MACE, and 125 patients experienced a MALE. Multivariable regression models, based on statistically proven covariables and literature, showed a significant association of Serpin G1 (HR 1.49; 95% CI 1.08 - 2.06; p = .016) and CD14 (HR 1.40; 1.03 - 1.90; p = .029) with MACE, and of Serpin G1 (HR 1.29; 1.07 - 1.57; p = .009) with MALE. Serpin G1 and CD14 plasma EV protein levels are associated with future MACE and MALE in patients with severe PAD.